|
|
|
|
|
13.10.25 - 23:57
|
XETR: DIVIDEND/INTEREST INFORMATION - 15.10.2025 - US00287Y1091 (XETRA)
|
|
|
Das Instrument 4AB US00287Y1091 ABBVIE INC. DL-,01 EQUITY wird cum Dividende/Zinsen gehandelt am 14.10.2025 und ex Dividende/Zinsen am 15.10.2025
The instrument 4AB US00287Y1091 ABBVIE INC. DL-,01 EQUITY has its pre-dividend/interest day on 14.10.2025 and its ex-dividend/interest day on 15.10.2025...
|
|
|
|
|
31.07.25 - 15:06
|
AbbVie: Bockstarke Zahlen – Dividenden-Aktie mit Kaufsignal (Der Aktionaer)
|
|
|
Der US-amerikanische Pharma-Konzern AbbVie hat hervorragende Zahlen zum zweiten Quartal vorgelegt und die Gewinnprognose nach oben geschraubt. Es zeichnet sich immer mehr ab, dass das Unternehmen die Lücke, die der einstige Top-Seller Humira nach dem Ablauf des Patentschutzes hinterlässt, schließen kann....
|
|
|
|
|
|
|
13.07.25 - 21:42
|
XETR: DIVIDEND/INTEREST INFORMATION - 15.07.2025 - 4AB (XETRA)
|
|
|
Das Instrument 4AB US00287Y1091 ABBVIE INC. DL-,01 EQUITY wird cum Dividende/Zinsen gehandelt am 14.07.2025 und ex Dividende/Zinsen am 15.07.2025
The instrument 4AB US00287Y1091 ABBVIE INC. DL-,01 EQUITY has its pre-dividend/interest day on 14.07.2025 and its ex-dividend/interest day on 15.07.2025...
|
|
|
|
|
|
|
|
|
|
|
13.01.25 - 23:48
|
XFRA : DIVIDEND/INTEREST INFORMATION - 15.01.2025 - US00287Y1091 (XETRA)
|
|
|
Das Instrument 4AB US00287Y1091 ABBVIE INC. DL-,01 EQUITY wird cum Dividende/Zinsen gehandelt am 14.01.2025 und ex Dividende/Zinsen am 15.01.2025
The instrument 4AB US00287Y1091 ABBVIE INC. DL-,01 EQUITY has its pre-dividend/interest day on 14.01.2025 and its ex-dividend/interest day on 15.01.2025...
|
|
|
13.01.25 - 23:45
|
XETR : DIVIDEND/INTEREST INFORMATION - 15.01.2025 - US00287Y1091 (XETRA)
|
|
|
Das Instrument 4AB US00287Y1091 ABBVIE INC. DL-,01 EQUITY wird cum Dividende/Zinsen gehandelt am 14.01.2025 und ex Dividende/Zinsen am 15.01.2025
The instrument 4AB US00287Y1091 ABBVIE INC. DL-,01 EQUITY has its pre-dividend/interest day on 14.01.2025 and its ex-dividend/interest day on 15.01.2025...
|
|
|
|
|
17.11.24 - 18:36
|
Can This Dividend King Ever Hit $400 After This Major Fail? (24/7 Wall St.)
|
|
|
24/7 Wall St. Insights: AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are now questioning the pharma's pipeline, raising doubts about how much ABBV stock can grow. Sit back and let dividends do the heavy lifting for a simple, steady path to serious wealth […]
The post Can This Dividend King Ever Hit $400 After This Major Fail? appeared first on 24/7 Wall St.....
|
|